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Motives and correlates of anabolic-androgenic steroid use with stimulant polypharmacy  
Abstract 
Individuals who use anabolic-androgenic steroids (AAS) may engage in concurrent 
psychoactive drug use recreationally and/or as an additional training aid. Aside from 
cannabis, individuals who use AAS most commonly report concurrent use of stimulants such 
as amphetamines and cocaine. In this study we examine demographic characteristics, 
frequency of heavy drinking and night-clubbing in a sample of 993 men from the Global 
Drug Survey (GDS) 2015 who reported both AAS and psychoactive drug use before 
exploring the relationship between motivation for AAS use and the propensity to 
concurrently engage with stimulant type substances. Results of a logistic regression analysis 
suggest that the propensity for concurrent use of AAS and stimulants is greater when AAS 
use is motivated by weight loss goals while performance goals are associated with reduced 
odds of concurrent stimulant use. Identifying individuals who are at risk of poly-drug use and 
associated harms can inform targeted harm reduction strategies.  
 
KEY WORDS: psychoactive drugs; anabolic steroids; poly-drug; stimulants 
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Motivations for anabolic steroid use associated with the co-use of illicit stimulants 
The harm associated with the use of illicit substances is a global health concern 
(Degenhardt, Hall, & Stone, 2016; Larance, Degenhardt, Copeland, & Dillon, 2008; 
Parkinson & Evans, 2006; Sagoe, Molde, Andreaseen, Torsheim & PAllesen, 2014; Sagoe & 
Pallesen, 2018). While rates of use and drugs of choice vary significantly across international 
contexts, the growing knowledge of and accessibility to, a diverse range of substances 
particularly via the internet is ubiquitous (Chandler & McVeigh, 2014; Griffiths & 
Mounteney, 2017; Hope et al., 2013). Poly-drug use – the concurrent use of multiple 
substances – is well documented in studies of individuals who use illicit drugs and is 
associated with increased risks of adverse health effects (Molero, Bakshi, & Gripenberg, 
2017) and can complicate medical responses in the case of an emergency event (Nieschlag & 
Vorona, 2015).  
Poly-drug use is a common feature of image and performance enhancement drug 
(IPED) protocols (Dodge & Hoagland, 2011; Hildebrandt, Langenbucher, Carr, & Sanjuan, 
2007; Ip et al., 2015; Korkia & Stimson, 1993; Lenehan, Bellis, & McVeigh, 1996; McBride, 
Williamson, & Petersen, 1996; Sagoe et al., 2015). Most of the research in this area focuses 
on poly-drug use as related to the practice of “stacking”. Stacking refers to the use of multiple 
types of steroids and other IPEDs to enhance performance, muscle building and fat loss, or to 
counter unwanted effects of AAS (Hoffman & Ratamess, 2006). However, there is also 
research with samples of bodybuilders, gym attendees and drug rehabilitation participants 
that suggests polysubstance use can extend beyond typical image and performance enhancing 
drugs to include illicit, psychoactive substances (Hope et al., 2013; Molero et al., 2017; 
Sagoe et al., 2015). Psychoactive substances may be taken to enhance the fat burning effects 
of AAS, aid sleep and recovery or manage pain (Ip et al., 2017; Molero et al., 2017; Sagoe et 
al., 2015). For example, stimulants such as amphetamines and cocaine can increase energy 
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allowing one to train harder while also incurring fat burning benefits (Nilsson, Baigi, 
Marklund, & Fridlund, 2001; Sagoe et al., 2015).  
There is also evidence that individuals who use steroids may engage in psychoactive 
drug use recreationally (Dodge & Hoagland, 2011; Hope et al., 2013; Ip et al., 2017; Molero 
et al., 2017; Sagoe et al., 2015; Salasuo & Piispa, 2012). Indeed, a study conducted on a large 
sample of gym attendees in Sweden found that AAS use was associated with lifetime history 
of psychoactive drug use and that previous psychoactive drug use separated AAS users from 
nonusers who had been offered AAS but declined (Hakansson, Mickelsson, Wallin, & 
Berglund, 2012). Another study reports that aside from cannabis, the three most commonly 
used psychoactive substances among gym attendees in Sweden are cocaine, amphetamine and 
ecstasy; approximately 40% of those who used drugs reported poly-drug use (Molero et al., 
2017). Individuals who had used illicit psychoactive substances were three times more likely 
to report use of AAS than gym attendees who had never used illicit, stimulant drugs. 
Using multiple substances simultaneously can increase the risk of negative impacts 
associated with any one of the drugs being ingested (Baggio, Studer, Mohler-Kuo, Daeppen, 
& Gmel, 2014; Connor, Gullo, White, & Kelly, 2014; Linn & Line, 2018). Here, we focus on 
the concurrent use of AAS and stimulants, specifically amphetamines and cocaine, (as 
opposed to opiates, hypnotics or illicitly used pharmaceuticals) for two key reasons: first, 
stimulants are the most frequently used psychoactive drug type among individuals who use 
steroids (aside from cannabis) and use can be related to training goals or recreational pursuits 
(Molero et al., 2017; Sagoe et al., 2015; Skarberg, Nyberg, & Engstrom, 2009), and second, 
research demonstrates that when used concurrently, AAS and stimulants work synergistically 
to exacerbate the cardiotoxic, and potentially the neurological, effect of either drug taken in 
isolation (Welder & Melchert, 1993). 
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Concurrent use of stimulants and steroids 
Adverse health outcomes associated with the chronic use of AAS are well 
documented. AAS use has been linked to acne, depression, hypogonadism, testicular atrophy 
and gynecomastia (Nieschlag & Vorona, 2015; Zahnow, McVeigh, Ferris, & Winstock, 
2017). The use of AAS can also have deleterious effects on the cardiovascular system leading 
to myocardial infarction, changes in cardiac structure and function, elevated blood lipid levels 
and hypertension (Angell et al., 2012; Baggish et al., 2017; Di Paolo et al., 2007; Fisher, 
Appleby, Rittoo, & Cotter, 1996; Güneþ, Erbaþ, Okuyan, Babalýk, & Gürmen, 2004; Liu & 
Wu, 2019; Montisci et al., 2012; Nieminen et al., 1996; Pereira dos Santos, Coutinho de 
Oliveira, & Silva, 2014; Santamarina, Besocke, Romano, Ioli, & Gonorazky, 2008; Thiblin, 
Lindquist, & Rajs, 2000). Most recently, scholars have found evidence that steroid use can 
lead to declines in cognitive functioning and changes in brain anatomy (Bjørnebekk et al., 
2017; Kanayama, Kean, Hudson, & Pope, 2013; Westlye, Kaufmann, Alnæs, Hullstein, & 
Bjørnebekk, 2017). Structural brain imaging reveals long-term exposure to AAS is associated 
with smaller overall brain volume and thinner cortex; effects that may underlie the noted 
correlation between AAS exposure and a range of psychiatric symptoms and cognitive 
deficits (Bjørnebekk et al., 2017). 
The cardiotoxic effects of stimulants are remarkably similar to those of AAS. The use 
of stimulants can lead to hypertension, acute and chronic heart failure, myocardial infarction, 
and increased heart rate (Ghuran & Nolan, 2000). Among otherwise low risk adults, the risk 
of acute myocardial infarction is 24 times greater in the first hour following cocaine 
consumption (Mittleman et al., 1999). Engaging in intense exercise and/ or the concurrent use 
of AAS alongside cocaine use serves to further exacerbate the risk myocardial events (Lange 
& Hillis, 2001; Welder & Melchert, 1993). Individuals who use AAS and cocaine, and also 
engage in intensive exercise, are at greatest risk of myocardial events because these drugs 
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work synergistically to enhance the drugs’ negative effects on the cardiovascular system 
(Welder & Melchert, 1993). Like AAS use, chronic stimulant exposure is also linked to a 
number of psychiatric symptoms and neural anatomical adaptations that can persist beyond 
cessation of substance use (Substance Abuse and Mental Health Services Administration, 
1999).    
Another factor that increases risk when using both AAS and stimulants is that steroids 
can slow and diminish the stimulant effects experienced by the user. This can lead to the user 
taking larger doses of the stimulant to gain the desired effect. Studies reveal the modulating 
effect of AAS on the psychoactive properties of stimulants such as cocaine and ecstasy 
(Kurling, Kankaanpää, & Seppälä, 2008; Lindqvist, Johansson-Steensland, Nyberg, & 
Fahlke, 2002; Phillis, Irvine, & Kennedy, 2000; Tseng, Rockhold, Hoskins, & Ho, 1994). 
Specifically, pre-treatment with AAS is associated with a decrease in the activation of the 
brain’s reward system and diminishes the effects of cocaine and ecstasy (Kurling et al., 2008; 
Lindqvist et al., 2002). AAS induced changes in the effects of stimulants may lead to reliance 
on larger doses to achieve the desired outcomes which, in turn, can lead to higher risk of 
overdose and dependence. While the studies reported here were carried out on animals and 
cannot be replicated on human samples, case studies support these findings. Psychostimulant 
use was detected in 23 of a total 24 cases of unexplained death involving AAS in NSW, 
Australia between 1995-2012 (Darke, Torok, & Duflou, 2014). Extensive cardiovascular 
disease was evident in all 24 cases despite a relatively low mean age of just 31.7 years. The 
study concluded that given the widespread use of psychostimulants in this group it was likely 
that the “combination of AAS and psychostimulants increases the risk of cardiovascular 
disease” (Darke et al., 2014). p.1028). A case study involving the sudden unexpected death of 
a female athlete similarly reported the concurrent use of AAS and ephedrine was the key 
factor causing death (Klötz, Petersson, Hoffman, & Thiblin, 2010). Another study associated 
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heart failure in a male athlete with past consumption of AAS, cocaine and amphetamines 
(Martinez-Quintana et al., 2013). 
A complicating factor when considering concurrent AAS and stimulant use is that the 
context in which non-training related stimulant use occurs may differ considerably from that 
of AAS use. The use of AAS is generally goal driven, planned and involves prolonged use. 
The benefits of AAS accumulate over time; they do not induce an immediate bodily sensation 
(e.g. feelings of euphoria). In contrast, the recreational use of stimulants tends to occur in 
social settings and may be opportunistic, impulsive and sporadic (Hildebrandt, 2015). The 
effects of stimulants are felt immediately; stimulants release large quantities of dopamine into 
the brain inducing a sense of euphoria (dela Peña, Gevorkiana, & Shi, 2015). Given the 
differences in both the social setting and normative patterns of AAS and recreational 
stimulant use, individuals may not recognise the two as inter-related or consciously 
acknowledge the potential for drug interaction. This aspect of the drug use again increases the 
risk of short and long term consequences by reducing an individual’s awareness of the 
potential for cross-drug interactions. 
Studies on specific samples of male steroid users including homosexual men (Ip et al., 
2017), recreational gym-goers (Hakansson et al., 2012; Molero et al., 2017) and bodybuilders 
(Sagoe et al., 2015) have demonstrated that concurrent AAS and stimulant use occurs within 
these population groups. Additionally, a number of studies have  identified individual level 
factors associated with this type of poly-drug use. One study, conducted by Petersson, 
Bengtsson, Voltaire-Carlsson, and Thiblin (2010) examined motivations for AAS use in a 
sample of 20 men attending an addiction clinic for dependence related to another 
psychoactive substance (alcohol, opiates, pharmaceuticals, other illicit drugs). Among these 
men, the most commonly reported motivation for AAS use was a desire to attain a nice body. 
Other motivating factors included: to become stronger; curiosity; because others were using, 
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and; to perform better in sport (Petersson et al., 2010). Skarberg, Nyberg and Engstrom’s 
(2011) study of 32 poly-drug users attending an addiction clinic revealed similar results. The 
men’s AAS use was motivated by muscle and strength gains while the use of amphetamine 
was driven by endurance and fat loss goals.  
Individuals who use steroids have reported using stimulants both recreationally and 
for sports performance enhancement (Angoorani, Narenjiha, Tayyebi, Ghassabian, Ahmadi, 
& Assari, 2009). Individual characteristics related to substance use broadly, including poor 
knowledge of associated risks, impulsivity and a proclivity for risk-taking may also be 
associated with problematic use of AAS and/or stimulant drugs (Kanayama et al, 2010; 
Miller et al., 2005). While research in this area is developing, currently, few studies elucidate 
factors associated with AAS related poly-drug use in non-clinical, non-athlete samples. A 
better understanding of motivations for AAS use in the context of also using stimulants may 
help to identify individuals at risk of this type of poly-drug use and, in turn, facilitate the 
design of targeted harm minimization strategies. 
The Current Study 
In the current study we explore patterns of poly-drug use in a sample of men who 
report lifetime use of AAS and a subset of the sample who report use of AAS in the last 12 
months. After establishing the relative frequency of co-occurring stimulant use compared to 
other drug types, in this sample of men of use AAS, we assess whether or not stated 
motivation for AAS use is associated with the propensity for individuals to also engage in 
stimulant use. This is important as there may be significant differences in motivations for 
AAS and stimulant use in samples used in previous research who were recruited from clinics, 
gyms and bodybuilding circles, compared to individuals primarily recruited as self-identified, 
recreational, psychoactive drug users. The way this group utilise stimulants may be 
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particularly problematic for thinking about interactions between AAS and stimulants; this 
group may also have higher levels of lifestyle risk. A better understanding of the 
characteristics associated with concurrent AAS and stimulant use can inform more effective 
harm minimization strategies and help to identify individuals most at risk of engaging in this 
form of poly-substance use. It is particularly important to explore this issue outside the 
sporting and bodybuilding population given that evidence demonstrates that steroids are 
utilized by a broad range of individuals in the general population for aesthetic purposes.  
Study Methods 
Study Design and Sample 
The Global Drug Survey (GDS) is an online, anonymous survey designed to capture 
in-depth information about the use of alcohol, tobacco and illicit substances. Since its 
inception in 2009, the GDS has been conducted annually. Here we use data from the GDS 
2015, which was collected between November 2014 and January 2015. A total of 89 509 
responses were completed during this time. The GDS survey is self-completed on a self-
nominating basis; in 2015, it was promoted in partnership with a range of media including 
national newspapers, magazines, web sites and social media outlets (Global Drug Survey, 
2015) and was available in 11 languages (English, German, Greek, Polish, French, Italian, 
Spanish, Portuguese, Flemish, Hungarian and Danish). Other publications provide details on 
the design, utility and limitations of the GDS (Barratt, Ferris, & Winstock, 2014; Global Drug 
Survey, 2015; Winstock, Lynskey, Borschmann, & Waldron, 2015). The GDS 2015 was 
approved by the Kings College Research Ethics Committee (PNM/14/15-18 Global Drug 
Survey). All participants provided written informed consent.  
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In this study we are interested in a sub-sample of the GDS; males who reported using 
injectable or oral anabolic steroids. A total of 993 (1.1%) men reported lifetime use of AAS, 
of these, 287 (0.3%) men reported using AAS in the last 12 months (see Table 1).  
Measures 
The GDS asks respondents to report on their use of more than 100 substances, 
including but not limited to, alcohol, tobacco, cannabis, amphetamines, cocaine, opiates, 
novel psychoactive substances, solvents and anabolic steroids. In the initial stages of the 
survey respondents are presented with a drug screen. For each substance, respondents are 
asked to report whether they have ever used; aged first used; when last used and frequency of 
use.  
Details of steroid use: Respondents who reported lifetime use of AAS in the drug screen are 
directed to a section of the GDS on performance enhancers. In this section of the survey 
respondents are asked to report on their lifetime and last year use of a range of performance 
enhancing drugs including AAS. To measure motivations for using these drugs, respondents 
are asked to rate on a scale ranging from (1) not important at all to (4) very important, how 
important are the following four goals: building muscle; weight loss; improving performance; 
improving my self-esteem/confidence.  
Details of stimulant use: Using the initial drug screen responses, we created a dichotomous 
variable to indicate respondents’ recent stimulant use. Respondents who reported they had 
used any form of amphetamine, methamphetamine, cocaine, crack cocaine, or novel 
psychoactive substances in the last 12 months were given a 1 on this variable. Respondents 
who did not report recent use of any of these substances were assigned a 0.  
 Details of other drug use:  Using the same process as outlined above, the initial drug screen 
responses were coded to compile a dichotomous indicator of recent depressant use and recent 
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use of hallucinogens. Respondents who reported they had used any form of cannabis; opioids; 
benzodiazepine (not prescribed to them); opium; GHB; GBL; methadone; nitrous or butane in 
the last 12 months were given a 1 on the depressant indicator variable and those who did not 
use any of the listed substances in the last 12 months were assigned a 0 on this variable. 
Respondents who reported they had used magic mushrooms; ketamine; LSD; PCP; DMT; 
peyote or mescaline in the last 12 months were given a 1 on the hallucinogen indicator and 
those who did not use these substances in the last 12 months were assigned a 0.    
Demographics characteristics, frequency of heavy drinking and night-clubbing: The GDS 
asks respondents to report their gender, age, sexual orientation, country of residence, 
employment status and highest level of education. In addition, the GDS collects information 
about aspects of respondents’ lifestyle. We use two items measuring, frequency of heavy 
drinking (eight drinks or more in a single session) and frequency of clubbing, to capture 
lifestyle risk. These behaviours may be associated with stimulant use (Leslie et al., 2015; Van 
Havere, Vanderplasschen, Lammertyn, Broekaert, & Bellis, 2011). Respondents are asked to 
report how often they have more than 8 drinks on one occasion: never; less than monthly; 
monthly; weekly; daily. For the purposes of the analyses the weekly and daily categories 
were aggregated. Respondents are also asked to report how often they go clubbing: never; 
less than once every three months; once every three months; once a month; once a fortnight; 
once or twice per week; three to four times per week; more than four times per week. For the 
purposes of the analyses the final three categories were aggregated to indicate clubbing 
frequency of weekly or more.  
Statistical Analyses  
The analyses proceed in two stages. First, we explore patterns of AAS and other 
substance use within the GDS sample using descriptive statistics. Second, we employ logistic 
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regression analysis to examine whether the odds of a recent AAS user concurrently using 
stimulants is associated with demographic characteristics, frequency of heavy drinking and 
night-clubbing  or particular motivations for using AAS. The dependent variable in the 
logistic regression is a dichotomous variable indicating recent use of both AAS and 
stimulants (0=no; 1=yes). The key independent variables measure the importance of four 
potential motivations for AAS use, to: gain muscle; lose weight; improve performance; 
increase self-esteem. Frequency of heavy drinking and night-clubbing are included to capture 
lifestyle factors associated with stimulant use. Demographic characteristics including age, 
region of residence, education and employment are included in the logistic regression as 
control variables. All independent variables are outlined in the variable descriptions above.  
Data were processed and analysed using Stata 14.0 (StataCorp, 2015). 
Results 
Descriptive statistics 
 The GDS sample comprised a total of 57, 484 men who had never used AAS; 993 
men who reported lifetime use of AAS and 287 men who reported using AAS in the last 12 
months (see Table 1). The most commonly used substance among all participants, including 
recent AAS users, was cannabis (see Table 2). After excluding cannabis from the depressant 
category (as cannabis is not illicit in all regions surveyed), the use of stimulant drugs in the 
last 12 months is the most common type of poly-drug use reported by recent AAS users. 
59.9% of recent AAS report also using stimulants in the last 12 months; 32.4% reporting 
using depressants (not including cannabis) and 51.6% reporting using hallucinogens in the 
last 12 months. Among individuals who recently used AAS, 41.8% also used ecstasy in the 
last 12 months; 38.7% used cocaine in the last 12 months and 20.6% used amphetamine in 
the last 12 months. 
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Logistic regression: predictors of recent stimulant use 
The final analytic cohort for the logistic regression comprised 215 men who reported 
using AAS in the last 12 months and also provided responses to the item related to 
motivations for AAS use. The average age of the analytic sample was 29.5 years (SD=10.4). 
The majority were employed (71.2%) and had engaged in post-school education (75.9%).  A 
total of 143 (66.5%) respondents reported using stimulants in the last 12 months.  
 
The results of the logistic regression analysis demonstrate that the odds of an 
individual who uses AAS to also use stimulants in the last 12 months is significantly higher 
among individuals who report that losing weight is quite important (OR=4.94, 95% CI: 1.66-
14.66, p<0.001) or very important (OR=3.71, 95% CI:1.70-12.84, p<0.05) when compared to 
individuals who report that losing weight is not important. of the likelihood of an individual 
who uses AAS to also use stimulants in the last 12 months is moderately higher among 
individuals who report that building muscle is very important (OR= 6.25, 95% CI: 1.28-
30.46, p<0.05) and is moderately lower among individuals who report that performance goals 
are very important (OR=0.30, 95% CI: 0.08-1.07) compared to those who report that building 
muscle and performance are not important, respectively. While p values suggest these 
associations are statistically significant, post-hoc Wald tests demonstrate moderate 
associations only (muscle building: 2=0.57, ns; performance: 2=0.09, ns). Frequency of 
heavy alcohol use is also associated with the propensity for AAS users to simultaneously 
engage in stimulant use; individuals who engage in heavy drinking weekly or more are more 
likely than those who do not engage in frequent heavy drinking to use both AAS and 
stimulants (OR=13.45, 95% CI: 3.14-57.55, p<0.001). Similarly, individuals who engage in 
frequent nightclubbing are more likely than those who do not go nightclubbing to report poly-
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drug use involving AAS and stimulants in the last 12 months. There was no significant effect 
of age, employment or education on the propensity for recent AAS users to also report using 
stimulants in the last 12 months. Results of the logistic regression model are presented in 
Table 4. 
Discussion 
The primary aim of this study was to explore poly-drug in a sample of men who use 
AAS and examine whether particular motivations for using AAS were associated with the 
concurrent use of illicit stimulants among the sample. Compared to AAS users who did not 
use stimulants, individuals who use AAS for aesthetic purposes, such as weight loss, are 
more likely to report concurrent use of AAS and stimulants than those who are not motivated 
by weight loss goals. Additionally, heavy drinking and night-clubbing at a higher frequencies 
was more common among individuals reporting concurrent use of stimulants and AAS than 
their non-stimulant using counterparts. Together, these findings suggest that in our sample 
those at greatest risk of engaging in concurrent use of stimulants and AAS are non-athletes 
concerned with the body enhancement benefits of anabolic steroids. Scholars have referred to 
this group as ‘aesthetes’ (Petersson et al., 2010) and the YOLO type (You Only Live Once) 
(Christiansen, Vinther, & Liokaftos, 2016; Zahnow et al., 2018). This group of AAS users are 
described as individuals who seek to improve their appearance and, in turn, self-confidence 
by enhancing muscularity and leanness through the use of steroids (Petersson et al., 2010). 
In this study, we focused on the concurrent use of AAS and stimulants for two 
reasons: first, because stimulants are the most frequently used psychoactive drug type among 
individuals who use steroids (with the exception of cannabis). Second, there are significant 
health risks associated with using both AAS and stimulants yet there is limited awareness of 
the synergistic properties of stimulants and AAS among users and service providers. Of 
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particular concern is the harm associated with using cocaine and alcohol while also on a cycle 
of AAS which can result in the formation of the toxic Cocaethylene (Dasgupta, 2017). In this 
study, with the exception of cannabis, stimulants were the most frequently used drug type 
among those who recently used AAS. Within the stimulant category, ecstasy was used most 
frequently by individuals who also used AAS, followed by cocaine and amphetamine. The 
results of this study provide support for previous research conducted with small samples of 
individuals who use AAS drawn from clinical populations (Kanayama, Cohane, Weiss & 
Pope, 2003; Skarberg, Nyberg & Engstrom, 2009) or with AAS using gym attendees/fitness 
participants (Kanayama, Pope, Cohane & Hudson, 2003; Ip, Barnett, Tenerowicz & Perry 
2011) where participants have reported using stimulants as training aids and/or recreationally. 
Our findings also align with those of research focussed on youth populations that indicates 
individuals who experiment with illicit drugs are more likely to use many drug types, 
including AAS and stimulants (Miller et al, 2005; Pallesen, Josendal, Johnsen, Larsen & 
Molde, 2006).  
Our study demonstrates that education on the additional implications of using AAS 
alongside stimulants should be provided to health care and drug service workers as well as 
substance users and potential users. Given the group of individuals engaging in this type of 
poly-drug use also report high levels of heavy drinking it is also important to highlight the 
impact of adding alcohol to the mix of AAS and stimulants. Concurrent use of AAS, 
stimulants and alcohol may significantly increase the risk of dehydration and related health 
concerns such as cardiac distress (Althobaiti & Sari, 2016; Miller, Barnes, Sabo, Melnick, & 
Farrell, 2002; Onakomaiya & Henderson, 2016). Interviews with individuals who use AAS 
have demonstrated that use of steroids is associated with greater propensity to experience 
negative consequences of alcohol use (Meilman, Crace, Presley, & Lyerla, 1995) and 
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drinking alcohol while AAS is also present in the body may increase the effects of alcohol on 
self-control and aggression (Meilman et al., 1995). 
Given the enhanced health risks associated with the concurrent use of AAS and 
stimulants and that effective approaches to preventing uptake and encouraging cessation of 
substance use are embedded in a comprehensive understanding of motivating factors and the 
benefits individuals derive from use, in this study we focused on identifying motivating 
factors for AAS use in this high risk group of users. Beyond achieving this primary aim, the 
study findings lead to an important observation; they highlight a group of males who engage 
in high risk, poly-drug use associated with unique health implications that go beyond those of 
individual substances. Also concerning is that risky, polysubstance use tends to co-occur with 
other high risk behaviours including heavy drinking, unprotected sex (Downing et al., 2011; 
Kokkevi et al., 2014) and violence (Steele & Peralta, 2017)  
Stigma and perceived stigma are barriers to engagement of both psychoactive drug 
users (Lloyd, 2013) and AAS users (Zahnow et al., 2017) in primary care, and there is no 
reason to believe that concomitant behaviours would serve to overcome this barrier. Given 
the complex chemical interactions between stimulants and AAS coupled with the large range 
of potential, acute and chronic adverse effects, it is clear that populations engaging in this 
form of poly-substance use would benefit from early interventions to reduce harms and 
monitor health. Given these individuals’ propensity to engage in a number of risky lifestyle 
behaviours combined with an apparent resistance to primary health care services, needle and 
syringe programs or steroid related services may offer a unique opportunity for meaningful, 
holistic health care interventions with this hard to reach, vulnerable population group. 
Providing educational materials at these services on the effects of drug interactions may be 
avenue for harm reduction.   
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Limitations 
We acknowledge that this study has a number of limitations. Firstly, the sample of 
individuals who report recent use of both AAS and stimulants is relatively small and it is 
restricted to self-identified, psychoactive drug users. Given the sampling method is self-
selection, the findings may not generalise to the broader AAS or stimulant using populations. 
Second, in reporting motivations for AAS use participants were limited to six options 
specified in the survey instrument1. We recognise that these do not cover the full spectrum of 
motivations that may drive AAS use. The survey also did not collect information on whether 
stimulant use was motivated by training goals or recreation. Given that individuals who 
reported concurrent use of stimulants and AAS in this sample also frequently engaged in 
heavy drinking, combined with the fact that the sample is a group of self-identified 
psychoactive substance users we suggest the majority of stimulant use is recreational. Finally, 
we recognise that while the clinical utility of the findings is limited, it is important to identify 
that a minority of AAS using individuals who are engaged in risky lifestyle behaviours such 
as heavy drinking and night-clubbing and/or are motivated to use AAS by weight loss goals 
may be at increased risk of adverse effects and require targeted approaches to reduce harms.  
Conclusions 
Overall, the findings presented here continue to highlight the need to move away from 
targeting all steroid prevention efforts at athletes and instead move toward prevention, 
education and health promotion strategies that target the general population.  Incorporating 
steroids into existing drug education programs in schools and providing information to 
facilitate risk reduction at environments where stimulant use is more likely to occur such as 
music  events and in night-time entertainment areas, alongside information on other types of 
                                                          
1 Four are reported in our study there were too few responses to each of the other two motivations to enable their 
inclusion in the logistic analysis. 
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recreational drugs, is a relatively low cost, harm reduction strategy that is easy to implement. 
Further, drug services such as needle and syringe programs and steroid outreach services 
have great potential to serve as avenues for delivering holistic health care and early 
intervention to prevent risky lifestyle activities to a high risk, health service resistant 
population group; currently this is an opportunity missed. The findings reported here 
demonstrate the importance of continually reviewing and renewing approaches to delivering 
safety messaging around drug use and moving away from the male athlete assumption in 
regards to steroid use (Miller et al., 2002).
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Table 1. Demographic characteristics  
Characteristics Never used 
(N=57,484) 
Never used 
(%) 
Ever used  
(N=993) 
Ever used  
(%) 
Used in the 
last 12 mths 
(N=287) 
Used in the 
last 12 mths 
(%) 
Age   mean min-max 30.17 (16-89) 32.03 (16-78) 31.05 (17-78) 
Region of residence        
Europe 47,387 (81.5) 525 (52.9) 148 (51.6) 
North America 3,308 (5.2) 104 (10.5) 29 (10.1) 
South Americas 3,102 (5.3) 243 (24.5) 66 (23.0) 
Oceania 4,073 (7.0) 104 (10.5) 37 (12.9) 
Other 536 (0.9) 17 (1.7) 7 (2.4) 
Education       
School only 13,603 (23.8) 237 (24.3) 67 (23.8) 
Tafe or certificate 19,804 (34.6) 376 (38.5) 118 (41.8) 
University 23,768 (41.6) 363 (37.2) 97 (34.4) 
Employment       
Employed 35,744 (62.1) 708 (72.2) 200 (70.7) 
Unemployed/student 21,865 (38.0) 272 (27.8) 83 (29.3) 
Steroid Use       
Age first used   23.37 (SD 8.95) 26.17 (SD 10.63) 
Inject steroid        
No oral only   453 (45.6) 102 (35.5) 
Inject    540 (54.4) 185 (64.5) 
NOTES: Total sample of GDS 2015 respondents was 89,509. Samples included here include only male respondents. 287 
individuals reported recent use of AAS but only 215 individuals completed the survey item assessing motivations so the 
logistic analyses utilises a sample of 215. Some percentage totals may not equate to 100 due to missing data. 
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Table 2. Use of psychoactive drugs and alcohol among males: GDS, lifetime AAS users and 
recent AAS users 
 Never 
used 
(N=57484) 
Never used 
(%) 
Ever used  
(N=993) 
Ever used  
(%) 
Used in the 
last 12 mths 
(N=287) 
Used in the 
last 12 mths 
(%) 
Frequency of alcohol use       
Not in the last 12 mths 3,240 (5.7) 126 (13.0) 28 (10.0) 
Monthly or less 7,671 (13.5) 178 (18.3) 67 (23.9) 
2-4 times a month 16,286 (28.6) 270 (27.8) 78 (27.9) 
2-3 times a week 19,944 (35.0) 283 (29.1) 80 (28.6) 
4 or more times a week 9,912 (17.4) 116 (11.9) 27 (9.6) 
Frequency of heavy drinking (8 
drinks or more) 
      
Never 8,589 (16.0) 110 (13.1) 36 (14.4) 
Less than monthly 20,355 (38.0) 363 (43.4) 111 (44.4) 
Monthly 14,410 (26.9) 204 (24.4) 48 (19.2) 
Weekly 9,330 (17.4) 144 (17.2) 51 (20.4) 
Daily 869 (1.6) 16 (1.9) 4 (1.6) 
Illicit Drug Use       
Min age used any illicit drug 
(excl. AAS) 
16.64 (SD 4.62) 16.94 (SD 5.22) 17.25 (SD 6.25) 
Have used a stimulant drug       
Ever 31,419 (54.0) 803 (80.9) 234 (81.5) 
In the last 12 months 19,300 (33.2) 491 (49.5) 172 (59.9) 
Have used a depressant drug       
Ever 48,504 (83.4) 934 (94.1) 266 (92.7) 
In the last 12 months 37,654 (64.8) 708 (71.3) 216 (75.3) 
Have used a other (incl. 
hallucinogens) drug  
      
Ever 34,815 (59.9) 811 (81.7) 227 (79.1) 
In the last 12 months 18,642 (32.1) 437 (44.1) 148 (51.6) 
Use of drugs in the last 12 
months 
      
Have not used any 
stimulants/ depressants/ 
hallucinogens 
16,498 (28.4) 169 (17.0) 29 (10.1) 
Depressants only 15,642 (26.9) 209 (21.1) 56 (19.5) 
Stimulants only 954 (1.6) 38 (3.8) 17 (5.9) 
Other only 2,231 (3.8) 34 (3.4) 5 (1.7) 
Two types 11,664 (20.1) 274 (27.6) 82 (28.6) 
All three types 11,147 (19.2) 269 (27.1) 98 (34.2) 
Specific drug types       
Have used amphetamines       
Mean min. age 20.37 (SD 5.53) 21.10 (SD 7.02) 21.09 (SD 7.52) 
Ever 19,703 (33.9) 489 (49.3) 141 (49.1) 
In the last 12 months 7,449 (12.8) 170 (17.1) 59 (20.6) 
Have used cocaine       
Mean min.age 21.85 (SD 5.02) 21.85 (SD 5.70) 22.05 (SD 6.30) 
Ever 19,706 (33.9) 620 (62.4) 176 (61.3) 
In the last 12 months 10,109 (17.4) 305 (30.7) 111 (38.7) 
Have used benzodiazepine        
Mean min.age 22.61 (SD 7.41) 23.98 (SD 7.80) 24.84 (SD 8.05) 
Ever 8,380 (14.4) 345 (34.7) 100 (34.8) 
In the last 12 months 5,131 (8.8) 219 (22.1) 81 (28.2) 
Have used cannabis       
Mean min.age 17.00 (SD 3.61) 17.58 (SD 4.76) 17.49 (SD 4.59) 
Ever 47,824 (82.3) 906 (91.2) 252 (87.8) 
In the last 12 months 36,108 (62.1) 625 (62.9) 181 (63.1) 
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Have used ecstasy       
Mean min.age 21.03 (SD 5.29) 21.61 (SD 5.76) 21.95 (SD 6.39) 
Ever 22,630 (38.9) 592 (59.6) 176 (61.3) 
In the last 12 months 14,840 (25.5) 332 (33.4) 120 (41.8) 
Have used LSD        
Mean min.age 20.55 (SD 4.34) 21.31 (SD 5.26) 21.50 (SD 5.58) 
Ever 14,874 (25.6) 452 (45.5) 118 (41.1) 
In the last 12 months 6,035 (10.4) 177 (17.8) 52 (18.1) 
Have used NPS       
Mean min.age 22.31 (SD 6.37) 24.87 (SD 8.21) 23.70 (SD 7.70) 
Ever 9,159 (15.7) 283 (28.5) 89 (31.0) 
In the last 12 months 4,880 (8.4) 114 (11.5) 40 (13.9) 
Have used opiates       
Mean min.age 22.48 (SD 7.80) 23.56 (SD 8.93) 23.24 (SD 8.66) 
Ever 10,211 (17.6) 304 (30.6) 85 (29.6) 
In the last 12 months 3,657 (6.3) 114 (11.5) 44 (15.3) 
Have used Other       
Mean min.age 18.38 (SD 5.63) 19.16 (SD 5.84) 19.69 (SD 6.47) 
Ever 33,370 (57.4) 754 (75.9) 205 (71.4) 
In the last 12 months 16,760 (28.8) 359 (36.2) 128 (44.6) 
NOTES: Total sample of GDS 2015 respondents was 89,509. Samples included here include only male respondents. 287 
individuals reported recent use of AAS but only 215 individuals completed the survey item assessing motivations so the 
logistic analyses utilises a sample of 215. Some percentage totals may not equate to 100 due to missing data 
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Table 3. Motivations of AAS use, drinking and night-clubbing behaviour in men reporting 
AAS use in last 12 months 
 N=215 
 N (%) 
Importance of goals: performance   
Not at all important 31 (14.4) 
A bit important 59 (27.4) 
Quite important 77 (35.8) 
Very important 48 (22.3) 
Importance of goals: weight loss   
Not at all important 74 (34.4) 
A bit important 64 (29.8) 
Quite important 42 (19.5) 
Very important 35 (16.3) 
Importance of goals: building 
muscle 
  
Not at all important 17 (7.9) 
A bit important 33 (15.4) 
Quite important 68 (31.6) 
Very important 97 (45.1) 
Importance of goals: self esteem   
Not at all important 37 (17.2) 
A bit important 59 (27.4) 
Quite important 65 (30.2) 
Very important 54 (25.1) 
Frequency of heavy drinking   
Never 29 (13.5) 
Less than monthly 96 (44.7) 
Monthly 40 (18.6) 
Weekly or more 50 (23.3) 
Frequency of clubbing   
Never 33 (15.4) 
Less than once every three 
months 
31 (14.4) 
Once every three months 35 (16.3) 
Once a month 44 (20.5) 
Once a fortnight 31 (14.4) 
Weekly or more 41 (19.1) 
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Table 4. Logistic regression predicting probability of stimulant use 
 Recent use of AAS & stimulant drugs (N=215) 
 β OR 95% CI 
Age 0.02 1.02 0.98,1.06 
Region of residence (ref: Europe)    
North America -0.93 0.39 0.11,1.47 
Oceania -0.64 0.53 0.15,1.87 
South Americas -0.89* 0.41 0.18,0.96 
Other 0.52 1.68 0.10,26.90 
Employment (ref: employed)    
Unemployed/student 0.53 1.71 0.75,3.90 
Education (ref: High school)    
Tafe or certificate -0.80 0.45 0.17,1.16 
University -0.28 0.76 0.28,2.09 
Importance of goals: performance  
(ref: not important) 
   
     A bit important 0.17 1.19 0.35,4.05 
     Quite important -0.17 0.84 0.26,2.69 
     Very important -1.21^ 0.30 0.08,1.08 
Importance of goals: weight loss 
(ref: not important) 
   
     A bit important 0.55 1.74 0.70,4.30 
     Quite important 1.60** 4.94 1.66,14.66 
     Very important 1.31* 3.71 1.07,12.85 
Importance of goals: building muscle 
(ref: not important) 
   
     A bit important 0.21 1.24 0.25,6.20 
     Quite important 0.59 1.81 0.39,8.38 
     Very important 1.83* 6.25 1.28,30.46 
Importance of goals: self esteem 
(ref: not important) 
   
     A bit important -0.51 0.60 0.21,1.77 
     Quite important -0.17 0.84 0.29,2.43 
     Very important -0.45 0.64 0.18,2.22 
Frequency of heavy drinking 
(ref: never) 
   
     Less than monthly 0.66 1.94 0.68,5.57 
     Monthly 0.99 2.69 0.77,9.48 
     Weekly or more 2.60*** 13.45 3.14,57.56 
Frequency of clubbing 
(ref: never) 
   
     Less than once every 3 months 0.35 1.42 0.39,5.12 
     Once every 3 months 2.00** 7.35 1.86,29.06 
     Once a month 1.25^ 3.49 0.99,12.33 
     Once a fortnight 1.70* 5.47 1.27,23.57 
     Weekly or more 0.76 2.14 0.55,8.32 
Model information    
Constant  -2.30 0.10 0.01,1.23 
χ2 68.67*** 
Pseudo R2 0.24 
Log likelihood -106.49 
NOTES: ^0.10, * p<0.05, ** p<0.01, ***p<0.001 
